Correction: Cancer therapeutic approach based on conformational stabilization of mutant p53 protein by small peptides (Oncotarget (2016) 7, (11817-11837) DOI: 10.18632/oncotarget.7857);Cancer therapeutic approach based on conformational stabilization of mutant p53 protein by small peptides

Oncotarget

Volumn 7, Issue 11, 2016, Pages 11817-11837

  Tal, Perry ^a   Eizenberger, Shay ^a   Cohen, Elad ^a   Goldfinger, Naomi ^a   Pietrokovski, Shmuel ^a   Oren, Moshe ^a   Rotter, Varda ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Conformation; p53; Peptides; Pre clinical; Reactivation

Indexed keywords

ANTINEOPLASTIC AGENT; PCAP 155 PEPTIDE; PCAP 174 PEPTIDE; PCAP 250 PEPTIDE; PCAP 308 PEPTIDE; PCAP 325 PEPTIDE; PCAP D60R PEPTIDE; PROTEIN P53; PROTEIN RAD9; UNCLASSIFIED DRUG; MUTANT PROTEIN; PEPTIDE FRAGMENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; BREAST CANCER; CANCER THERAPY; COLON CANCER; CONTROLLED STUDY; DRUG MECHANISM; IN VIVO STUDY; MOUSE; NONHUMAN; OVARY CANCER; PEPTIDE LIBRARY; PHAGE DISPLAY; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEIN MOTIF; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY; TUMOR XENOGRAFT; VALIDATION PROCESS; ANIMAL; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; GENETICS; HUMAN; METABOLISM; MUTATION; NEOPLASM; NUDE MOUSE; PATHOLOGY; TUMOR CELL CULTURE;

ANIMALS; APOPTOSIS; CELL PROLIFERATION; HUMANS; MICE; MICE, NUDE; MUTANT PROTEINS; MUTATION; NEOPLASMS; PEPTIDE FRAGMENTS; PROTEIN CONFORMATION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84962859916     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.26921     Document Type: Erratum

References (56)

1. Levine JA. p53, the cellular gatekeeper for growth and division. Cell. 1997; 88:323-331.
2. Vousden KH and Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer. 2002; 2:594-604.
3. el-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW and Vogelstein B. Definition of a consensus binding site for p53. Nat Genet. 1992; 1:45-49.
4. Jordan JJ, Menendez D, Inga A, Noureddine M, Bell DA and Resnick MA. Noncanonical DNA motifs as transactivation targets by wild type and mutant p53. PLoS Genet. 2008; 4:e1000104.
5. Veprintsev DB and Fersht AR. Algorithm for prediction of tumour suppressor p53 affinity for binding sites in DNA. Nucleic Acids Res. 2008; 36:1589-1598.
6. Vogelstein B, Lane D and Levine AJ. Surfing the p53 network. Nature. 2000; 408:307-310.
7. Soussi T and Wiman KG. Shaping genetic alterations in human cancer: the p53 mutation paradigm. Cancer Cell. 2007; 12:303-312.
8. Hainaut P, Olivier M and Pfeifer GP. TP53 mutation spectrum in lung cancers and mutagenic signature of components of tobacco smoke: lessons from the IARC TP53 mutation database. Mutagenesis. 2001; 16:551-553; author reply 555-556.
9. Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC and Hainaut P. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat. 2002; 19:607-614.
10. Oren M. Decision making by p53: life, death and cancer. Cell Death Differ. 2003; 10:431-442.
11. Joerger AC, Allen MD and Fersht AR. Crystal structure of a superstable mutant of human p53 core domain. Insights into the mechanism of rescuing oncogenic mutations. J Biol Chem. 2004; 279:1291-1296.
12. Joerger AC, Ang HC, Veprintsev DB, Blair CM and Fersht AR. Structures of p53 cancer mutants and mechanism of rescue by second-site suppressor mutations. J Biol Chem. 2005; 280:16030-16037.
13. Friedlander P, Legros Y, Soussi T and Prives C. Regulation of mutant p53 temperature-sensitive DNA binding. J Biol Chem. 1996; 271:25468-25478.
14. Barak Y, Gottlieb E, Juven-Gershon T and Oren M. Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential. Genes Dev. 1994; 8:1739-1749.
15. Midgley CA, Desterro JM, Saville MK, Howard S, Sparks A, Hay RT and Lane DP. An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo. Oncogene. 2000; 19:2312-2323.
16. Bode AM and Dong Z. Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer. 2004; 4:793-805.
17. Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L, Newman J, Reczek EE, Weissleder R and Jacks T. Restoration of p53 function leads to tumour regression in vivo. Nature. 2007; 445:661-665.
18. Christophorou MA, Martin-Zanca D, Soucek L, Lawlor ER, Brown-Swigart L, Verschuren EW and Evan GI. Temporal dissection of p53 function in vitro and in vivo. Nat Genet. 2005; 37:718-726.
19. Wang W, Rastinejad F and El-Deiry WS. Restoring p53-dependent tumor suppression. Cancer Biol Ther. 2003; 2:S55-63.
20. Selivanova G and Wiman KG. Reactivation of mutant p53: molecular mechanisms and therapeutic potential. Oncogene. 2007; 26:2243-2254.
21. Wright JD and Lim C. Mechanism of DNA-binding loss upon single-point mutation in p53. J Biosci. 2007; 32:827-839.
22. Bullock AN, Henckel J and Fersht AR. Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy. Oncogene. 2000; 19:1245-1256.
23. Canadillas JM, Tidow H, Freund SM, Rutherford TJ, Ang HC and Fersht AR. Solution structure of p53 core domain: structural basis for its instability. Proc Natl Acad Sci U S A. 2006; 103:2109-2114.
24. Wang PL, Sait F and Winter G. The 'wildtype' conformation of p53: epitope mapping using hybrid proteins. Oncogene. 2001; 20:2318-2324.
25. Vojtesek B, Dolezalova H, Lauerova L, Svitakova M, Havlis P, Kovarik J, Midgley CA and Lane DP. Conformational changes in p53 analysed using new antibodies to the core DNA binding domain of the protein. Oncogene. 1995; 10:389-393.
26. Ravera MW, Carcamo J, Brissette R, Alam-Moghe A, Dedova O, Cheng W, Hsiao KC, Klebanov D, Shen H, Tang P, Blume A and Mandecki W. Identification of an allosteric binding site on the transcription factor p53 using a phage-displayed peptide library. Oncogene. 1998; 16:1993-1999.
27. Halazonetis TD, Davis LJ and Kandil AN. Wild-type p53 adopts a 'mutant'-like conformation when bound to DNA. The EMBO journal. 1993; 12:1021-1028.
28. Halazonetis TD and Kandil AN. Conformational shifts propagate from the oligomerization domain of p53 to its tetrameric DNA binding domain and restore DNA binding to select p53 mutants. The EMBO journal. 1993; 12:5057-5064.
29. Rivlin N, Katz S, Doody M, Sheffer M, Horesh S, Molchadsky A, Koifman G, Shetzer Y, Goldfinger N, Rotter V and Geiger T. Rescue of embryonic stem cells from cellular transformation by proteomic stabilization of mutant p53 and conversion into WT conformation. Proceedings of the National Academy of Sciences of the United States of America. 2014; 111:7006-7011.
30. Furth N, Bossel Ben-Moshe N, Pozniak Y, Porat Z, Geiger T, Domany E, Aylon Y and Oren M. Down-regulation of LATS kinases alters p53 to promote cell migration. Genes & Development. 2015; 29:2325-2330.
31. Zhang W, Guo XY, Hu GY, Liu WB, Shay JW and Deisseroth AB. A temperature-sensitive mutant of human p53. The EMBO journal. 1994; 13:2535-2544.
32. Ludwig RL, Bates S and Vousden KH. Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function. Molecular and Cellular Biology. 1996; 16:4952-4960.
33. Martin AC, Facchiano AM, Cuff AL, Hernandez-Boussard T, Olivier M, Hainaut P and Thornton JM. Integrating mutation data and structural analysis of the TP53 tumor-suppressor protein. Hum Mutat. 2002; 19:149-164.
34. Wang Z and Sun Y. Targeting p53 for Novel Anticancer Therapy. Translational Oncology. 2010; 3:1-12.
35. Cheok CF, Verma CS, Baselga J and Lane DP. Translating p53 into the clinic. Nat Rev Clin Oncol. 2011; 8:25-37.
36. Zawacka-Pankau J and Selivanova G. Pharmacological reactivation of p53 as a strategy to treat cancer. Journal of Internal Medicine. 2015; 277:248-259.
37. Pearson S, Jia H and Kandachi K. China approves first gene therapy. Nat Biotech. 2004; 22:3-4.
38. Friedler A, Veprintsev DB, Hansson LO and Fersht AR. Kinetic instability of p53 core domain mutants: implications for rescue by small molecules. J Biol Chem. 2003; 278:24108-24112.
39. Takimoto R, Wang W, Dicker DT, Rastinejad F, Lyssikatos J and el-Deiry WS. The mutant p53-conformation modifying drug, CP-31398, can induce apoptosis of human cancer cells and can stabilize wild-type p53 protein. Cancer Biol Ther. 2002; 1:47-55.
40. Bykov VJ, Issaeva N, Selivanova G and Wiman KG. Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database. Carcinogenesis. 2002; 23:2011-2018.
41. Bykov VJ, Zache N, Stridh H, Westman J, Bergman J, Selivanova G and Wiman KG. PRIMA-1(MET) synergizes with cisplatin to induce tumor cell apoptosis. Oncogene. 2005; 24:3484-3491.
42. FitzGerald K. In vitro display technologies - new tools for drug discovery. Drug Discov Today. 2000; 5:253-258.
43. Menendez A and Scott JK. The nature of target-unrelated peptides recovered in the screening of phage-displayed random peptide libraries with antibodies. Anal Biochem. 2005; 336:145-157.
44. Lu J and Sloan SR. An alternating selection strategy for cloning phage display antibodies. J Immunol Methods. 1999; 228:109-119.
45. Ishikawa K, Ishii H, Murakumo Y, Mimori K, Kobayashi M, Yamamoto K, Mori M, Nishino H, Furukawa Y and Ichimura K. Rad9 modulates the P21WAF1 pathway by direct association with p53. BMC molecular biology. 2007; 8:37.
46. Robertson AD and Murphy KP. Protein Structure and the Energetics of Protein Stability. Chemical Reviews. 1997; 97:1251-1268.
47. Borghouts C, Kunz C and Groner B. Current strategies for the development of peptide-based anti-cancer therapeutics. J Pept Sci. 2005; 11:713-726.
48. Borghouts C, Kunz C and Groner B. Peptide aptamers: recent developments for cancer therapy. Expert Opin Biol Ther. 2005; 5:783-797.
49. Loffet A. Peptides as drugs: is there a market? J Pept Sci. 2002; 8:1-7.
50. Ellerby HM, Arap W, Ellerby LM, Kain R, Andrusiak R, Rio GD, Krajewski S, Lombardo CR, Rao R, Ruoslahti E, Bredesen DE and Pasqualini R. Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med. 1999; 5:1032-1038.
51. Pernot M, Vanderesse R, Frochot C, Guillemin F and Barberi-Heyob M. Stability of peptides and therapeutic success in cancer. Expert Opinion on Drug Metabolism & Toxicology. 2011; 7:793-802.
52. Galaxy: an Open Platform for Accessible, Reproducible, and Transparent Biomedical Research.
53. Blankenberg D, Taylor J, Schenck I, He J, Zhang Y, Ghent M, Veeraraghavan N, Albert I, Miller W, Makova K, Hardison R and Nekrutenko A. A framework for collaborative analysis of ENCODE data: making large-scale analyses biologist-friendly. Genome Res. 2007; 17:960 - 964.
54. Altschul SF, Madden TL, Schäffer AA, Zhang J, Zhang Z, Miller W and Lipman DJ. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Research. 1997; 25:3389-3402.
55. Henikoff S, Henikoff JG, Alford WJ and Pietrokovski S. Automated construction and graphical presentation of protein blocks from unaligned sequences. Gene. 1995; 163:GC17-GC26.
56. Stambolsky P, Weisz L, Shats I, Klein Y, Goldfinger N, Oren M and Rotter V. Regulation of AIF expression by p53. Cell Death Differ. 2006; 13:2140-2149.